Literature DB >> 12635764

Persistent hyperinsulinaemic hypoglycaemia of infancy: case report.

S Semiz1, I Bircan, S Akçurin, E Mihçi, M Melikoglu, G Karagüzel, B Kiliçaslan, G Karpuzoğlu.   

Abstract

Hyperinsulinism, although rare, is the most common cause of persistent hyperinsulinaemic hypoglycaemia in infancy. Because of persistent hypoglycaemia, serious difficulties are encountered in the long term management of this condition. A male neonate, after an uncomplicated full-term pregnancy, had been admitted to another hospital with convulsions on the third post-natal day. Meningitis had been suspected at that time and treated with phenobarbital and he had been discharged from the hospital. At three-months old he was referred to our department for persistent convulsions and lethargy. His parents were of 1st degree consanguinity. His blood glucose level was found to be 24 mg/dl (1.33 mmol/L). Because of the dangerously high insulin level during hypoglycaemia (insulin/glucose > 0.3), the absence of ketonuria, and the need for a high dose of glucose infusion (> 15 mg/kg/min) to achieve normoglycaemia and a glycaemic response to glucagon despite the hypoglycaemia, a diagnosis of persistent hyperinsulinaemic hypoglycaemia of infancy was made. Since maximal doses of prednisone, glucagon, diazoxide, octreotide and high infusion of glucose were ineffective in achieving normoglycaemia, a subtotal (80%) pancreatectomy was done. Postoperatively intermittent hypoglycaemic episodes continued. These were controlled with low doses of octreotide. Histology revealed diffuse adenomatous hyperplasia (nesidoblastosis). The boy is now in the sixth post-operative month and developing normally.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12635764     DOI: 10.4314/eamj.v79i10.8821

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  2 in total

Review 1.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565

2.  A combination of nifedipine and octreotide treatment in an hyperinsulinemic hypoglycemic infant.

Authors:  Erdem Durmaz; Sarah E Flanagan; Mesut Parlak; Sian Ellard; Sema Akcurin; Iffet Bircan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.